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In this study all the new synthesized compounds of sulfonamide bearing 4-((2-(5-bromo-1H-pyrazolo[3,4-b]pyridin-1-
yl)-2-oxoethyl)amino)-N-(various-substitutions)benzenesul-fonamide have been synthesized by using 1-(5-bromo-1H-
pyarazolo[3,4-b]pyridin-1yl)-2-chloroethanone which has been fused with various sulfa drugs in presence of potassium 
carbonate and DMF. All the derivatives have been recognized by physical properties like melting point and characterization 
by elemental analysis (CHNS) and various spectral techniques such as FT-IR, 1H and 13C NMR, and ESI-MS. The series of 
these pyrazolo[3,4-b]pyridin bearing sulfonamide have been synthesized and the final derivatives have been evaluated for 
bioactivity such as anti-bacterial activity against gram +ve and gram −ve and also screened for their in vitro anti tubercular 
activity against Mycobacterium tuberculosis H37RV. The results for the synthesized compounds have been compared against 
standard drugs. 
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Sulfonamide compounds having an important class  
of synthetic therapeutic agents for various disease  
and bacteriostatic antibiotics. The key of some 
compounds containing sulfonamides group such as 
Sulfamethoxazole, Sulfapyridine, Sulfathiazole, 
Sulfamethazine (Figure 1) possessing interesting of 
bioactivity. 
Sulfonamides possess different of pharmacological 















Other side the key intermediate of the substituted 
of pyarazolo scaffold such as pyrazolo[3,4-b]pyridine 
have been most interesting scaffold due to possessing 
considerable attention for medicinal discovery and 
wide range of significant biological therapeutic 














 treatment of 

















b]pyridine also inhibitors of erectile dysfunctions
24
 
For development and found biologically evolutions, in 
this ongoing work we synthesized potent and new 
way to fused pyrazolo[3,4-b]pyridine with various 
sulfonamide (sulfa drugs) and well recognized 
pharmacophore with different range of activity such 
as antibacterial activity against gram +ve and gram -
ve strains with minimum inhibition concentration 
(MIC) and also in vitro anti tubercular activity against 




Material and methods 
For the synthesis of 4-((2-(5-bromo-1H-pyrazolo 
[3,4-b]pyridin-1-yl)-2-oxoethyl)amino)-N-(various-
substitutions)benzenesulfonamide a novel series 
(Scheme I, Table I) the following chemical and 
reagents were used all sulfa drugs and 5-bromo-1H-
pyrazolo[3,4-b]pyridine were acquired from 
commercial sources (Sigma-Aldrich). and Potassium 
Carbonate (K2CO3), dimethyl formamide, (DMF), 
chloro-acetyl chloride (CAC) and triethyl amine 
(TEA) from Merck (Germany). Pre coated aluminum 
sheets (silica gel 60 F254, Merck) were used for thin-
layer chromatography (TLC) and spots were 
visualized under ultraviolet light. Melting point (m.p.) 




were measured by using a Mel-temp instrument, and 
results are uncorrected. Infra-red spectra was recorded 
on Shimadzu spectrophotometer in the frequency 
range 4000-400 cm−1 using KBr pellet disc, 1H and 
13
C NMR spectra were recorded on Bruker at 400 
MHz and 100 MHz in DMSO solution and chemical 
shifts were recorded in parts per million (δ, ppm) with 
TMS at the internal reference. Advion expression 
CMS, USA were used for recorded mass spectra. The 
compound were analyzed for Carbon, Hydrogen, 
Nitrogen oxygen and Sulphur were estimated on 
CHNS analyzer serial No.: 15084053 
 
General synthesis of 1-(5-bromo-1H-pyrazolo[3,4-
b]pyridine1-yl)-2chloroethanone 
A mixture of 5-Bromo-1H-pyrazolo[3,4-b]pyridine 
(PRPy) (0.01 mol) with Chloroacetyl chloride (0.015 
mol) and 4-5 drops of TEA(triethylamine) in 25 mL 
DMF as solvent in RBF at 0-5ºC. The reaction 
mixture was stirred for 12 hr at RT. The Completion 
of the reaction was Checked by TLC using toluene: 
Acetone (30%). The solution poured in to ice water. 
Obtained solid was filtered by vacuum pump and 





Above synthesized derivative of 1-(5-bromo-1H-
pyarazolo[3,4-b]pyridin-1yl)-2-chloroethanone (0.01 
mol) was reacted with various sulfa drugs (0.01 mol) 
in presence of potassium carbonate (0.02 mol) and 
DMF. The reaction was stirred at RT for 8 hr. The 
Completion of the reaction was checked by TLC 
using toluene: Acetone (20%). The product was 
poured into water and stirred for 1 hr. The obtained 
solid was collected and dried. Crystallize into ethanol. 
 
Antibacterial activity 
Antibacterial activities of all synthesized 
compounds A-J were evaluated by reported in vitro 
agar well diffusion method
25
. The inhibitions zone 
was measured were the microorganism inhibited after 
the incubation was done and were compare with 
 
 




Scheme I — Synthetic route of compounds A-J 
 




standard streptomycin (1000µg/mL). shown in 
Table II. 
The minimum concentration or maximum dilution 
which was required for kill bacterial growth regard as 
minimum Inhibitory concentration (MIC). MIC 
values shown in Table III. 
 
In vitro anti-mycobacterial activity 
According to Lowenstein Jensen (L-J) medium the 
all synthesized compounds A-J were assayed for Anti- 
mycobacterial activity, following reported method
25
. 
The colony forming units (c.f.u) was determination by 
taken 10 fold dilution of standard drug 1mg/mL 
 
Table I — Physical characterization data and substitutions of present synthetic compounds 






B  ~210 408.98 C14H12BrN5O3S 72.3 
C 
 
248-250 491.32 C18H15BrN6O4S 70.5 
D 
 
~238 488.32 C18H14BrN7O3S 70.8 
E 
 
271-273 516.37 C20H18BrN7O3S 69.7 
F 
 





~265 518.34 C19H16BrN7O4S 68.1 
H 
 
231-233 487.33 C19H15BrN6O3S 69.4 
I 
 
~229 474.26 C16H13BrN5NaO4S 68.3 
J 
 
~215 452.29 C15H14BrN7O3S 67.2 
 







 Enterobacter aerogens 
MTCC No. 8558 
Escherichia coli  
MTCC No. 1610 
Micrococcus luteus  
MTCC No. 11948 
Bacillus cereus  
MTCC No. 8558 
Mean value  





Mean value for  





Mean value for  





Mean value  





A 28 1.166 23 0.958 29 1.208 29 1.208 
B 19 0.791 20 0.833 22 0.917 19 0.791 
C 32 1.333 30 1.250 29 1.208 30 1.250 
D 29 1.208 28 1.166 30 1.250 26 1.083 
E 19 0.791 22 0.917 18 0.750 21 0.875 
F 21 0.875 19 0.791 21 0.875 18 0.750 
G 18 0.750 27 1.125 17 0.708 20 0.833 
H 18 0.750 25 1.041 15 0.625 19 0.791 
I 30 1.250 31 1.291 30 1.250 24 1.000 
J 20 0.833 17 0.708 26 1.083 18 0.750 
Std 24 - 24 - 24 - 24 - 
 




Mycobacterium tuberculosis suspension with marked 
on L-J medium. H2KO4P (potassium di hydrogen 
phosphate), MgSO4 (magnesium sulfate anhydrous), 
magnesium citrate, (Loba chemie), L-asparagines, 
malachite green and glycerol these all reagents was 
included in L-J medium. The concentration of 2% v/v 
and 4% v/v were dissolved into 100 mL culture 
medium for inspections. The medium were allow to 
stay for incubated at 37ºC for 42 days with using 
standard bacterial suspension. standard drug rifamacine 
and isoniazide was used as medium for comparison of 
colony forming units (c.f.u) on drug free control, 
reading was taken weekly. percentage inhibition was 








c = Control 
t = Test 
 
Characterization 
The synthesized compounds of 4-((2-(5-bromo-1H-
pyrazolo[3,4-b]pyridin-1-yl)-2-oxoethyl)amino)-N-
(various-substitutions)benzenesulfonamide were 
characterized by IR, 1H and 13C NMR, ESI-MS and 






A: Yellow solid, m.p ~255ºC. Anal. Calcd for 
C17H13BrN6O3S2: C, 41.39; H, 2.66; N, 17.03; O, 9..73; 
S, 13.00. Found C, 41.40; H, 2.62; N, 17.10; O, 9.77, 
S, 12.97%. IR (KBr): 3390 (sulfa-NH), 3220 
(pyrazolo-NH) 3022 (C-Hstr saturated hydrocarbon), 
1705 (C=O) 1615 (C=Nstr) 1345 (C-Nstr), 1520 
(aromatic ring), 1396 Asy., 1142 Syn., (O=S=O), 1520 
cm
−1
 (thiazole ring); 
1
H NMR (400 MHz, DMSO); δ 
3.52, 3.77 (s 2H -CH2), 7.19-7.46 (d, aromatic 
Protons), 7.54-7.57 (d, aromatic Protons), 6.62, 7.79 (d 
1H and d 1Hthiazole), 7.78 (s 1H Ar-H Pyridine), 8.30 (s, 
1H pyrazolo) 7.46 (s 1H Ar-H Pyridine), 11.82 (s, 1H -
NH); 
13
C NMR (100 MHz, DMSO-d6); ESI-MS: m/z 






B: Yellow solid, m.p ~210ºC. Anal. Calcd for 
C14H12BrN5O3S: C, 40.99; H, 2.95; N, 17.07; O, 
11..70; S, 7.82. Found C, 41.01; H, 2.91; N, 17.10; O, 
11.77, S, 7.77%. IR (KBr): 3470 (Asy-NH), 3422 
(Sym-NH), 3220 (pyrazolo-NH) 3011 (C-Hstr 
saturated hydrocarbon), 1710 (C=O) 1617 (C=Nstr) 
1352 (C-Nstr), 1580 (aromatic ring), 1357 Asy., 1162 
cm
−1
 Syn., (O=S=O); 
1
H NMR (400 MHz, DMSO): δ 
4.18, 4.39 (s 2H -CH2), 7.18-7.20 (d, aromatic 
Protons), 7.84-7.86 (d, aromatic Protons), 6.82 (s, 
SO2NH), 8.31 (s 1H Ar-H Pyridine), 8.52 (s, 1H 
pyrazolo) 8.69 (s 1H Ar-H Pyridine), 11.98 (s, 1H -
NH); 
13
C NMR (100 MHz, DMSO-d6); ESI-MS: m/z 






benzenesulfonamide, C: Yellow light solid, m.p 248-
 







 Enterobacter aerogens  
MTCC No. 8558 
Escherichia coli  
MTCC No. 1610 
Micrococcus luteus  
MTCC No. 11948 
Bacillus cereus  
MTCC No. 8558 
MIC(µg/mL) MIC(µg/mL) MIC(µg/mL) MIC(µg/mL) 
A 12.5 25 12.5 50 
B 200 200 100 200 
C 25 12.5 25 12.5 
D 50 100 50 100 
E 100 200 200 200 
F 200 100 100 50 
G 200 200 200 200 
H 100 50 100 50 
I 100 25 50 25 
J 100 200 50 100 
Std 6.25 6.25 3.125 6.25 
 




250ºC. Anal. Calcd for C18H15BrN6O4S: C, 44.00; H, 
3.08; N, 17.11; O, 13..03; S, 6.53. Found C, 44.05; H, 
3.02; N, 17.10; O, 13.07, S, 6.47%. IR (KBr): 3395 
(sulfa-NH), 3240 (pyrazolo-NH) 3034 (C-Hstr saturated 
hydrocarbon), 1718 (C=O) 1617 (C=Nstr) 1312 (C-Nstr), 





H NMR (400 MHz, DMSO): δ 2.05 (s, -
CH3), 4.22, 4.42 (s 2H -CH2), 7.15-7.17 (d, aromatic 
Protons), 7.77-7.79 (d, aromatic Protons), 7.41, (s 
1Hmethoxazole), 8.30 (s 1H Ar-H Pyridine), 8.22 (s, 1H 
pyrazolo) 8.58 (s 1H Ar-H Pyridine), 12.05 (s, 1H -
NH); 
13
C NMR (100 MHz, DMSO-d6); ESI-MS: m/z 






benzenesulfonamide, D: Yellow light solid, m.p 
~238ºC. Anal. Calcd for C18H14BrN7O3S: C, 44.27; H, 
2.89; N, 20.08; O, 9.83; S, 6.57. Found C, 44.25; H, 
2.92; N, 20.02; O, 9.87, S, 6.47%. IR (KBr): 3340 
(sulfa-NH), 3277 (pyrazolo-NH) 3058 (C-Hstr 
saturated hydrocarbon), 1725 (C=O) 1620 (C=Nstr) 
1315 (C-Nstr), 1551 (aromatic ring), 1351 Asy., 1149 
cm
−1
 Syn., (O=S=O); 
1
H NMR (400 MHz, DMSO): δ 
3.79,4.01 (s 2H -CH2), 7.18-7.21 (d, aromatic 
Protons), 7.54-7.56 (d, aromatic Protons), 6.55, (m, 
1Hpyrimidin), 6.61,7.42 (d, 2Hpyrimidin), 8.22 (s 1H Ar-H 
Pyridine), 7.58 (s, 1H pyrazolo) 7.78 (s 1H Ar-H 
Pyridine), 11.83 (s, 1H -NH), 12.46 (s, 1H -NH); 
13
C NMR (100 MHz, DMSO-d6); ESI-MS: m/z Calcd 






yl)benzenesulfonamide, E: White solid, m.p 271-
273ºC. Anal. Calcd for C20H18BrN7O3S: C, 46.52; H, 
3.51; N, 18.99; O, 9.30; S, 6.21. Found C, 46.55; H, 
3.52; N, 18.92; O, 9.27, S, 6.23%. IR (KBr): 3355 
(sulfa-NH), 3245 (pyrazolo-NH) 3057 (C-Hstr saturated 
hydrocarbon), 1710 (C=O) 1622 (C=Nstr) 1322 (C-Nstr), 





H NMR (400 MHz, DMSO): δ 2.19 (s, 3H 
CH3) 2.25 (s, 3H CH3), 4.22,4.45 (s 2H -CH2), 7.17-7.19 
(d, aromatic Protons), 7.79-7.81 (d, aromatic Protons), 
6.92, (s, 1Hpyrimidin), 8.32 (s 1H Ar-H Pyridine), 8.17 (s, 
1H pyrazolo) 8.66 (s 1H Ar-H Pyridine), 12.22 (s, 1H -
NH); 13C NMR (100 MHz, DMSO-d6); ESI-MS: m/z 





yl)benzenesulfonamide, F: Yellow solid, m.p 
>262ºC. Anal. Calcd for C19H16BrN7O3S: C, 45.43; H, 
3.21; N, 19.52; O, 9.55; S, 6.38. Found C, 45.42; H, 
3.22; N, 19.52; O, 9.57, S, 6.37%. IR (KBr): 3350 
(sulfa-NH), 3241 (pyrazolo-NH) 3052 (C-Hstr 
saturated hydrocarbon), 1715 (C=O) 1621 (C=Nstr) 
1321 (C-Nstr), 1550 (aromatic ring), 1365 Asy., 1153 
cm
−1
 Syn., (O=S=O); 
1
H NMR (400 MHz, DMSO): δ 
2.19 (s, 3H CH3), 4.18,4.39 (s 2H -CH2), 7.18-7.20 (d, 
aromatic Protons), 7.75-7.77 (d, aromatic Protons), 
6.82, (s, 1Hpyrimidin), 8.22 (d, 1Hpyrimidin), 8.31 (s 1H Ar-
H Pyridine), 8.10 (s, 1H pyrazolo) 8.56 (s 1H Ar-H 
Pyridine), 12.10 (s, 1H -NH); 
13
C NMR (100 MHz, 







yl)benzenesulfonamide, G: Yellow solid, m.p 
~265ºC. Anal. Calcd for C19H16BrN7O4S: C, 44.03; H, 
3.11; N, 18.92; O, 12.35; S, 6.19. Found C, 44.05; H, 
3.15; N, 18.82; O, 12.47, S, 6.17%. IR (KBr): 3352 
(sulfa-NH), 3245 (pyrazolo-NH) 3077 (C-Hstr saturated 
hydrocarbon), 1722 (C=O) 1631 (C=Nstr) 1322 (C-Nstr), 





H NMR (400 MHz, DMSO): δ 3.55 (s, 3H 
CH3), 4.24,4.49 (s 2H -CH2), 7.22-7.24 (d, aromatic 
Protons), 7.82-7.84 (d, aromatic Protons), 7.05, (d, 
1Hpyrimidin), 7.11 (d, 1Hpyrimidin), 8.24 (d, 1Hpyrimidin), 8.35 
(s 1H Ar-H Pyridine), 8.10 (s, 1H pyrazolo) 8.56 (s 1H 
Ar-H Pyridine), 12.10 (s, 1H -NH); 
13
C NMR (100 







H: Light yellow solid, m.p 231-233ºC. Anal. Calcd for 
C19H15BrN6O3S: C, 46.83; H, 3.10; N, 17.25; O, 9.85; 
S, 6.58. Found C, 46.85; H, 3.15; N, 17.22; O, 9.87, S, 
6.57%. IR (KBr): 3350 (sulfa-NH), 3252 (pyrazolo-
NH) 3072 (C-Hstr saturated hydrocarbon), 1717 (C=O) 
1652 (C=Nstr) 1323 (C-Nstr), 1575 (aromatic ring), 1355 
Asy., 1154 cm
−1
; Syn., (O=S=O); 
1
H NMR (400 MHz, 
DMSO): δ 4.23,4.44 (s 2H -CH2), 7.21-7.23 (d, 
aromatic Protons), 7.80-7.82 (d, aromatic Protons), 
6.82-8.37 (m, 6Hpyridine), 11.89 (s, 1H -NH); 
13
C NMR 
(100 MHz, DMSO-d6); ESI-MS: m/z Calcd 486.01. 

















amide, I: Light yellow solid, m.p ~229ºC. Anal. Calcd 
for C16H13BrN5NaO4S: C, 40.52; H, 2.76; N, 14.77; O, 
13.49; S, 6.76. Found C, 40.55; H, 2.78; N, 14.75; O, 
13.47, S, 6.82%. IR (KBr): 3172 (pyrazolo-NH) 3088 
(C-Hstr saturated hydrocarbon), 1720 (C=O) 1645 
(C=Nstr) 1337 (C-Nstr), 1553 (aromatic ring), 1347 
Asy., 1140 cm
−1
; Syn., (O=S=O). ); 
1
H NMR (400 
MHz, DMSO): δ 1.95 (s, 3H CH3), 4.21,4.40 (s 2H -
CH2), 7.18-7.20 (d, aromatic Protons), 7.81-7.83 (d, 
aromatic Protons), 8.21 (s 1H Ar-H Pyridine), 8.64 (s 
1H Ar-H Pyridine), 12.21 (s, 1H -NH); 
13
C NMR (100 







benzenesulfonamide, J: Light yellow solid, mp 
~215ºC. Anal. Calcd for C15H14BrN7O3S: C, 39.83; H, 
3.12; N, 21.68; O, 10.61; S, 7.09. Found C, 39.85; H, 
3.15; N, 21.65; O, 10.67, S, 7.05%. IR (KBr): 3475 (Asy-
NH), 3424 (Sym-NH), 3155 (pyrazolo-NH) 3052 (C-Hstr 
saturated hydrocarbon), 1720 (C=O), 1645 (C=Nstr) 1356 





H NMR (400 MHz, DMSO): δ 
4.22,4.45 (s 2H -CH2)7.14-7.18 (d, aromatic Protons), 
7.94-7.96 (d, aromatic Protons), 6.81 (m, br, 1Hguanidine), 
8.24 (s 1H Ar-H Pyridine), 8.67 (s 1H Ar-H Pyridine), 
12.10 (s, 1H -NH); 
13
C NMR (100 MHz, DMSO-d6); 




Results and Discussion 
 
Antibacterial activity 
Antibacterial activity completed by in vitro agar 
well diffusion method. The percentage of zone 
inhibition was calculated in term of active zone index 
in which the streptomycin was used as standard drug 
(Figure 2). 








The synthesized this new series of 4-((2-(5-bromo-
1H-pyrazolo[3,4-b]pyridin-1-yl)-2-oxoethyl)amino)-
N-(various-substitutions)benzenesulfonamide A-J 
were evaluated their anti bacterial activity with 
streptomycin as standard drugs, the concentration was 
1000 µg/mL. The considerable results showed for all 
new final synthesized compounds of A-J were good, 
moderate and lowest active against gram negative and 
Gram positive bacteria. On the bases of this results we 
terminate that zone inhibition of antibacterial activity 
of A, C, D and I, were increased than their sulfa drugs 
distinct while the another compounds inhibition zones 
were decreased compared to standard, shown in 
Table II. 
The MIC values of these A-J series showed 
substantial results (Figure 3). For all derivatives such 
as A,C,D and I compounds showed very good MIC 
values shown in Table III and other compound shown 
moderate to average MIC values. Although, the 
compounds A and C showed very good zone inhibition 
activity as well as in MIC for all bacterial strains. 
 
In vitro anti-mycobacterial activity 
In vitro anti-mycobacterial activity of Tested all 
synthesized compounds showed excellent to average % 
inhibition against Mycobacterium tuberculosis H37Rv. 
From the data (%) results of inhibition values showed 
C (75.20 %), F (80.99 %), and G (81.81 %) had 
showed excellent inhibition, while other had good to 
average % inhibition. 
From the experiment results MIC of the in vitro 
anti-mycobacterial activity showed also excellent for 
C, F and G in sequences (25, 6.25, 6.25 µg/mL), 
 
 
Figure 2 — Antibacterial activity of compounds A-J 




while other derivatives showed 25 to 200 µg/mL 
against Mycobacterium tuberculosis H37Rv (Table IV). 
 
Conclusion 
In summarized, for this present work all synthesized 
compounds A-J were derived by the different 
sulfonamides (sulfa-drugs) (dSD) clubbed with  
5-Bromo-1H-pyrazolo[3,4-b]pyridine (PRPy) via 
chloro acetyl chloride (CAC). All target  
compounds were screened for their antibacterial 
activity against Gram positive and Gram negative 
bacteria, compounds A, C, D and I shown good  
potent inhibitions. Moreover, compounds C, F and G 
had showed excellent inhibition for in vitro  
anti tubercular activity against Mycobacterium 
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